.:. Consulter > Par domaine > Sciences du Vivant/Cancérologie .:.

938 documents classés par :  date titre 1er auteur

1 - 2 - 3 - 4 - 5 - 6 - 7 ...

Genetic variations of the A13/A14 repeat located within the EGFR 3(prime) untranslated region have no oncogenic effect in patients with colorectal cancer. Sarafan-Vasseur N., Sefrioui D., Tougeron D., Lamy A., Blanchard F., Le Pessot F., Di Fiore F., Michel P., Bézieau S., Latouche J.-B. et al BMC Cancer 13, 1 (2013) 183 [inserm-00813520 - version 1]

Lymphoma B-cell responsiveness to CpG-DNA depends on the tumor microenvironment. Ben Abdelwahed R., Cosette J., Donnou S., Crozet L., Ouakrim H., Fridman W. H., Sautès-Fridman C., Mahjoub A., Fisson S. Journal of Experimental & Clinical Cancer Research 32, 1 (2013) 18 [inserm-00811929 - version 1]

Phase I study of OM-174, a lipid A analogue, with assessment of immunological response, in patients with refractory solid tumors. Isambert N., Fumoleau P., Paul C., Ferrand C., Zanetta S., Bauer J., Ragot K., Lizard G., Jeannin J.-F., Bardou M. BMC Cancer 13, 1 (2013) 172 [inserm-00813522 - version 1]

(Angiotensin-2 type 1 receptors (AT1R) and cancers). Dolley-Hitze T., Verhoest G., Jouan F., Le Pogamp P., Arlot-Bonnemains Y., Oger E., Belaud-Rotureau M.-A., Rioux-Leclercq N., Vigneau C. Néphrologie & Thérapeutique 9, 2 (2013) 85-91 [inserm-00814037 - version 1]

The MUC4 mucin mediates gemcitabine resistance of human pancreatic cancer cells via the Concentrative Nucleoside Transporter family. Skrypek N., Duchêne B., Hebbar M., Leteurtre E., Van Seuningen I., Jonckheere N. Oncogene 32, 13 (2013) 1714-23 [inserm-00807837 - version 1]

Expression screening of cancer/testis genes in prostate cancer identifies nr6a1 as a novel marker of disease progression and aggressiveness. Mathieu R., Evrard B., Fromont G., Rioux-Leclercq N., Godet J., Cathelineau X., Guillé F., Primig M., Chalmel F. Prostate (2013) epub ahead of print [inserm-00821963 - version 1]

Apoptosis and p53 are not involved in the anti-tumor efficacy of (125)I-labeled monoclonal antibodies targeting the cell membrane. Paillas S., Boudousq V., Piron B., Kersual N., Bardiès M., Chouin N., Bascoul-Mollevi C., Arnaud F.-X., Pèlegrin A., Navarro-Teulon I. et al Nuclear Medicine and Biology (2013) epub ahead of print [inserm-00815724 - version 1]

Estrogen receptor-positive/human epidermal growth factor receptor 2-negative breast tumors: Early prediction of chemosensitivity with (18) F-fluorodeoxyglucose positron emission tomography/computed tomography during neoadjuvant chemotherapy. Groheux D., Hatt M., Hindié E., Giacchetti S., de Cremoux P., Lehmann-Che J., Martineau A., Marty M., Cuvier C., Cheze Le Rest C. et al Cancer (2013) epub ahead of print [hal-00777901 - version 1]

Statins: Perspectives in cancer therapeutics. Laurent C., Le Jossic‐corcos C. Digestive and Liver Disease Mars, 9 (2013) epub ahead of print [inserm-00815063 - version 1]

The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment. Ascierto P., Capone M., Urba W., Bifulco C., Botti G., Lugli A., Marincola F., Ciliberto G., Galon J., Fox B. Journal of Translational Medicine 11, 1 (2013) 54 [inserm-00804641 - version 1]

1 - 2 - 3 - 4 - 5 - 6 - 7 ...